Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Alveolo Biosciences conference call to discuss its second quarter 2022 business highlights. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open up the call for your questions. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press the star and the number one on your telephone keypad. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to Kendra Sweeney of Avello. Please proceed. Thank you. This morning, we issued two press releases. one announcement that includes a summary of our recent business highlights and second quarter financial results, and another regarding the succession plan for CEO Simba Gill. These releases and a recording of the call are available at www.avelobio.com under the Investors tab. Speaking on the call today will be Simba Gill, CEO, and Lord Ara Darzi, Chair of the Avelo Board of Directors. Before we begin, I would like to remind everyone that statements made during this conference call that do not relate to matters of historical fact, including statements about our objectives and anticipated clinical milestones, the impact of any of our product candidates, and the timing and results of any clinical studies should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual results could differ materially from those indicated by the forward-looking statements due to the impact of many factors. ...